

Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis

Christiane Stern¹, Cecilia De Freitas¹, Michel Bazinet², Vincent Mackiewicz³, Ségolène Brichler⁴, Emmanuel Gordien⁴, Marc Bourlière⁵, Stéphane Chevaliez⁶, Andrew Vaillant²

1. Service de Hépatologie, AP-HP Hôpital Beaujon, Clichy, France, 2. Replicor Inc. Montreal, Canada, 3. Service de Virologie, Hôpital Bichat, Paris, France 4. Centre national de référence des hépatite B, C et Delta – Laboratoire associé, Hôpital Avicenne, Bobigny, France, 5. Service Hépto-Gastro-Entérologie, Hôpital Saint-Joseph, Marseille, France, 6. Service de Virologie, Hôpital Henri Mondor, Créteil, France

Poster SAT-183

Introduction

The only treatment option for chronic hepatitis delta (CHD) patients with decompensated cirrhosis is liver transplantation. REP 2139-Mg blocks the assembly and secretion of HBV subviral particles and hepatitis delta antigen function, providing multiple effects against both HBV and HDV infection. Compassionate access to REP 2139-Mg is being provided under the Replicor Compassionate Access Program (RCAP, NCT05683548).

Aim

The objective of this study is to describe the safety and efficacy of REP 2139-Mg in CHD patients with decompensated cirrhosis.

Method

Compassionate use in the first three CHD patients with decompensated cirrhosis to receive REP 2139-Mg 250 mg QW SC and TDF 245 mg QD PO for 48 weeks was approved in France by the ANSM. Clinical, biological, virological and imaging data were collected at baseline and every week for the first month, then every month.

Conclusions

SC REP 2139-Mg is well tolerated and safe in patients with CHD decompensated cirrhosis

Liver function improvement with significant ascites reversal was rapid, occurring after only 4 weeks of treatment.

Lack of ALT / AST flares may reflect altered immunological status in cirrhotic livers

Host mediated ALT/AST flares are frequent with NAPs + pegIFN in non-cirrhotic patients

HBV-HDV functional cure with HBsAg loss and HBs seroconversion appears achievable for the first time in this special population, which could prevent the need for a future liver transplant.

References

Shamur et al., Hepatol. 2017; 66: 504A
Bazinet et al., Lancet Gastroenterol Hepatol 2017; 2: 877-889
Bazinet et al., Hepatology Comm. 2020 5: 189-202
Bazinet et al., Gastroenterol. 2020; 158: 2180-2194

Boulon et al., Hepatol. 2021; 74: 512A
Bazinet et al., J Viral Hep 2021; 28: 817-825
Bazinet et al., Hepatol Comm 2021; 28: 817-825

Contact information

Christiane Stern: christiane.stern@aphp.fr

Andrew Vaillant: availlant@replicor.com

Results

Table 1. Patient baseline characteristics			
Patient	1 (RCAP 5)	2 (RCAP 8)	3 (RCAP 11)
Age (years)	56	56	47
Sex	Female	Female	Male
Ethnicity	Caucasian	African	African
ALT (U/L) ^a	168	64	89
Total bilirubin (μmol/L)	15	44	24
Albumin (g/L)	28	24	24
Platelets (10 ⁹ /L)	56	90	35
INR	1.26	1.92	1.67
Child-Pugh / MELD	B8 / 9	C12 / 17	C10 / 13
HDV genotype*	1	5	5
HDV RNA (IU/mL)	1.09x10 ⁷	4285	34138
HBsAg (IU/mL)	1177	4270	1273
HBsAg status	Negative	Negative	Positive
HBV DNA (IU/mL)	Target not detected	Target not detected	< 10 IU/mL (LLOQ)

^aNormal ALT: <34 U/L in female and <45 U/L in male

*Done centrally at Hôpital Avicenne




Figure 1. Safety and efficacy of REP 2139-Mg in HDV decompensated cirrhosis. No hematological or other systemic AE related to REP 2139-Mg have been observed to date.